Treatment of Refractory Schizophrenia With Riluzole
What is the purpose of this trial?
The proposed study would evaluate the benefits of riluzole add-on treatment to patients with schizophrenia who are already receiving medications, but still experience symptoms. Neuroprotective medication riluzole is currently approved for treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease), a severe neurological illness. Due to its unique mechanism of action, riluzole, if effective in helping the symptoms of schizophrenia, would open novel directions in treatment of schizophrenia.
- 18 Years - 65 Years
- Stanley Medical Research Institute
- May 2002
- Last Updated:
- Jan 20, 2009
- Study HIC#:
Clinicaltrials.gov ID: NCT00375050